| Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population A Koliada, G Syzenko, V Moseiko, L Budovska, K Puchkov, V Perederiy, ... BMC microbiology 17 (1), 120, 2017 | 367 | 2017 |
| Gut microbiota: A player in aging and a target for anti-aging intervention AM Vaiserman, AK Koliada, F Marotta Ageing research reviews 35, 36-45, 2017 | 169 | 2017 |
| Epigenetic programming by early‐life stress: Evidence from human populations AM Vaiserman Developmental Dynamics 244 (3), 254-265, 2015 | 119 | 2015 |
| Radiation hormesis: historical perspective and implications for low-dose cancer risk assessment AM Vaiserman Dose-Response 8 (2), dose-response. 09-037. Vaiserman, 2010 | 116 | 2010 |
| Association between type 2 diabetes and prenatal exposure to the Ukraine famine of 1932–33: a retrospective cohort study LH Lumey, MD Khalangot, AM Vaiserman The lancet Diabetes & endocrinology 3 (10), 787-794, 2015 | 107 | 2015 |
| Early-life exposure to endocrine disrupting chemicals and later-life health outcomes: an epigenetic bridge? A Vaiserman Aging and disease 5 (6), 419, 2014 | 97 | 2014 |
| Anti-aging pharmacology: promises and pitfalls AM Vaiserman, V Lushchak, AK Koliada Ageing research reviews 31, 9-35, 2016 | 82 | 2016 |
| Hormesis and epigenetics: is there a link? AM Vaiserman Ageing research reviews 10 (4), 413-421, 2011 | 81 | 2011 |
| Early-life nutritional programming of longevity AM Vaiserman Journal of developmental origins of health and disease 5 (5), 325-338, 2014 | 77 | 2014 |
| Epidemiologic evidence for association between adverse environmental exposures in early life and epigenetic variation: a potential link to disease susceptibility? A Vaiserman Clinical epigenetics 7 (1), 96, 2015 | 71 | 2015 |
| Seasonality of birth in children and young adults (0–29 years) with type 1 diabetes in Ukraine AM Vaiserman, B Carstensen, VP Voitenko, MD Tronko, VI Kravchenko, ... Diabetologia 50 (1), 32-35, 2007 | 71 | 2007 |
| Hormesis, adaptive epigenetic reorganization, and implications for human health and longevity AM Vaiserman Dose-Response 8 (1), dose-response. 09-014. Vaiserman, 2010 | 66 | 2010 |
| Health impacts of low-dose ionizing radiation: current scientific debates and regulatory issues A Vaiserman, A Koliada, O Zabuga, Y Socol Dose-Response 16 (3), 1559325818796331, 2018 | 56 | 2018 |
| Metformin as a geroprotector: experimental and clinical evidence V Piskovatska, N Stefanyshyn, KB Storey, AM Vaiserman, O Lushchak Biogerontology 20 (1), 33-48, 2019 | 48 | 2019 |
| Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives A Vaiserman, O Lushchak Journal of Translational Medicine 15 (1), 1-9, 2017 | 48 | 2017 |
| HDAC inhibitors: A new promising drug class in anti-aging research EG Pasyukova, AM Vaiserman Mechanisms of ageing and development 166, 6-15, 2017 | 48 | 2017 |
| Epigenetic drugs: a novel anti-aging strategy? A Vaiserman, EG Pasyukova Frontiers in genetics 3, 224, 2012 | 43 | 2012 |
| Early-life origin of adult disease: evidence from natural experiments A Vaiserman Experimental gerontology 46 (2-3), 189-192, 2011 | 43 | 2011 |
| The role of the TOR pathway in mediating the link between nutrition and longevity O Lushchak, O Strilbytska, V Piskovatska, KB Storey, A Koliada, ... Mechanisms of ageing and development 164, 127-138, 2017 | 42 | 2017 |
| Fucoxanthin and lipid metabolism: A minireview K Muradian, A Vaiserman, KJ Min, VE Fraifeld Nutrition, Metabolism and Cardiovascular Diseases 25 (10), 891-897, 2015 | 42 | 2015 |
Koliada AlexanderGerontology Institute, Ukraine. DIAGEN labVerified email at diagen.com.ua
